Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Med Chem ; 182: 111633, 2019 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-31461688

RESUMEN

Recently, selective inhibition of BET BD2 is emerging as a promising strategy for drug discovery. Despite significant progress in this area, systematic studies of selective BET BD2 inhibitors are still few. In this study, we report the discovery of a potent and selective BET BD2 inhibitor BY27 (47). Our high resolution co-crystal structures of 47/BRD2 BD1 and BD2 showed that the triazole group of 47, water molecules, H433 and N429 in BRD2 BD2 established a water-bridged H-bonding network, which is responsible for the observed selectivities. DNA microarray analysis of HepG2 cells treated with 47 or OTX015 demonstrated the transcriptome impact differences between a BET BD2 selective inhibitor and a pan BET inhibitor. In a MV4-11 mouse xenograft model, 47 caused 67% of tumor growth inhibition and was less toxic than a pan BET inhibitor 1 at high doses. We conclude that the improved safety profile of selective BET BD2 inhibitors warrant future studies in BET associated diseases.


Asunto(s)
Azepinas/química , Descubrimiento de Drogas , Proteínas/antagonistas & inhibidores , Pirazoles/química , Animales , Azepinas/síntesis química , Azepinas/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Células Hep G2 , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Modelos Moleculares , Estructura Molecular , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , Dominios Proteicos , Proteínas/metabolismo , Pirazoles/síntesis química , Pirazoles/farmacología , Relación Estructura-Actividad
2.
Ann Clin Psychiatry ; 28(4): 239-244, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27901516

RESUMEN

BACKGROUND: Psychotropic drug changes during medical hospitalizations may lead to psychiatric and medical readmissions. METHODS: One-year hospitalization records of nursing home patients with chronic mental illness and a psychotropic drug change during medical admission were reviewed. We calculated the readmission rates for 30, 60, and 90 days; the classes of the psychotropic drugs changed; the reason for change; and the specialties of the responsible physicians. The readmission rates were compared with those of an age-matched control group. RESULTS: The changes were associated with an increase in psychiatric readmission rates of 2.7% (30 days), 5.4% (60 days), and 14.9% (90 days). The 90 days readmission rate reached statistical significance (14.9% vs 2.7%; OR = 6.29; P = .020). The family practice team was responsible for the highest psychiatric readmission rate (18.4%). The most significant reasons for change included human errors (up to 40%), which is alarming. CONCLUSIONS: Judicious changes, attempts at re-titration, and appropriate documentation of reasons for change on discharge records may reduce the readmission rates.


Asunto(s)
Hospitalización , Trastornos Mentales/tratamiento farmacológico , Readmisión del Paciente/estadística & datos numéricos , Servicio de Psiquiatría en Hospital/estadística & datos numéricos , Psicotrópicos/uso terapéutico , Humanos , Pautas de la Práctica en Medicina , Estudios Retrospectivos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA